Fewer than a tenth of people that would benefit from obesity jabs like Wegovy have access to them, states the WHO as it releases its first advice on the therapies.
Given in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for more widespread and fairer availability to these injectable treatments.
Per forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.
"Our latest guidance acknowledges that excess weight is a long-term condition that can be addressed with holistic and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are major barriers to universal availability to the treatments that can help people shift significant body mass, says the organization.
Weight-Loss Drug Supply Crisis
Even under the present most optimistic case, the manufacturing of such drugs would only suffice for around 100 million people – fewer than 10% of eligible patients, as stated by the health organization.
The guideline encourages countries and companies to expand access, through strategies like licensing agreements.
Exclusive production rights on the active ingredient – the primary ingredient of Novo Nordisk's Wegovy – is set to lapse in a number of countries in 2026.
How Weight-Loss Jabs Operate
These medications mimick a natural hormone to slow digestion, curb appetite and enhance feelings of fullness so users consume fewer calories.
Patients usually begin shedding pounds within a few weeks of commencing the regular doses.
Research suggests users may regain a significant portion within a year of stopping the treatment, as their typical hunger resume.
To be above a healthy weight elevates your chance for experiencing diseases, like type 2 diabetes, cardiovascular issues, stroke, and specific malignancies.
Obesity affects individuals in every country and was associated with millions of fatalities worldwide in 2024, as per the WHO.
